ThromboGenics Starts Trading as Part of the BEL20 Index Today

        ThromboGenics Starts Trading as Part of the BEL20 Index Today

  PR Newswire

  LEUVEN, Belgium, March 18, 2013

LEUVEN, Belgium, March 18, 2013 /PRNewswire/ --

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical
company focused on developing and commercializing innovative ophthalmic
medicines, announces that the Company will start trading as part of the BEL20
index on the Euronext stock exchange today. 

The BEL20 index is a real-time index reflecting the continuous price evolution
of the 20 most liquid Belgian shares listed on Euronext Brussels and serves as
Blue-chip index for Euronext Brussels. The weight of the index constituents is
based on their market capitalization adjusted for free float by using a free
float banding system.

ThromboGenics will be included in the BEL20 index as of today.

Patrik De Haes, CEO of ThromboGenics, commented, " We are very pleased to be
now included in the BEL20 index which reflects the tremendous progress
ThromboGenics has made since its inception. The inclusion in the index will
further increase the Company ' s access to a broader pool of investors and
enhance ThromboGenics '  already strong profile as one of the leading
biotechnology companies in  Europe . "

About ThromboGenics

ThromboGenics is an integrated biopharmaceutical company focused on developing
and commercializing innovative ophthalmic medicines. The Company's lead
product, JETREA ^® (ocriplasmin), has been approved by the US FDA for the
treatment of symptomatic VMA and was launched in January 2013. In Europe, it
has been approved for the treatment of vitreomacular traction (VMT), including
when associated with macular hole of diameter less than or equal to 400
microns. 

In March 2012, ThromboGenics signed a strategic partnership with Alcon
(Novartis) for the commercialization of JETREA ^® outside the United States.
Under this agreement, ThromboGenics could receive up to a total of €375
million in up-front and milestone payments. It will receive significant
royalties from Alcon's net sales of JETREA ^® . ThromboGenics and Alcon intend
to share the costs equally of developing JETREA ^® for a number of new
vitreoretinal indications.

ThromboGenics is also further exploring anti-PIGF (Placental Growth Factor),
formerly referred to as TB-403, for the treatment of ophthalmic and oncology
indications.

ThromboGenics is headquartered in Leuven, Belgium, and has-offices in Iselin,
NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext
Brussels exchange under the symbol THR. More information is available at
http://www.thrombogenics.com .

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking".
Such forward-looking statements are based on current expectations, and,
accordingly, entail and are influenced by various risks and uncertainties. The
Company therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume an obligation to update or
revise any forward-looking statement, whether as a result of new information,
future events or any other reason. Additional information concerning risks and
uncertainties affecting the business and other factors that could cause actual
results to differ materially from any forward-looking statement is contained
in the Company's Annual Report.

This press release does not constitute an offer or invitation for the sale or
purchase of securities or assets of ThromboGenics in any jurisdiction.  No
securities of ThromboGenics may be offered or sold within the United States
without registration under the U.S. Securities Act of 1933, as amended, or in
compliance with an exemption therefrom, and in accordance with any applicable
U.S. state securities laws.

For further information please contact: Wouter Piepers, Global Head of
Corporate Communications +32-16-75-13-10 / +32-478-33-56-32
wouter.piepers@thrombogenics.com Dr. Patrik De Haes, CEO +32-16-75-13-10
Patrik.dehaes@thrombogenics.com Chris Buyse, CFO +32-16-75-13-10
Chris.buyse@thrombogenics.com Citigate Dewe RogersonDavid Dible/ Nina Enegren/
Sita Shah Tel: +44-20-7638-9571  sita.shah@citigatedr.co.uk The Trout Group
(US investor relations)Todd James/ Simon Harnest Tel: +1-646-378-2926
tjames@troutgroup.com
 
Press spacebar to pause and continue. Press esc to stop.